Beacon Investment Advisory Services Inc. Sells 6,163 Shares of Danaher Corporation $DHR

Beacon Investment Advisory Services Inc. lessened its holdings in shares of Danaher Corporation (NYSE:DHRFree Report) by 8.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 70,980 shares of the conglomerate’s stock after selling 6,163 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Danaher were worth $13,520,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Main Street Group LTD bought a new stake in shares of Danaher in the first quarter worth about $25,000. JPL Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth approximately $25,000. Elevated Capital Advisors LLC acquired a new stake in Danaher during the 4th quarter worth approximately $26,000. WFA of San Diego LLC bought a new position in Danaher in the second quarter valued at approximately $26,000. Finally, Hilton Head Capital Partners LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. DZ Bank assumed coverage on shares of Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. Citigroup assumed coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price for the company. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. UBS Group dropped their price target on Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Argus cut their price target on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Read Our Latest Report on Danaher

Danaher Stock Performance

DHR opened at $204.34 on Friday. The business’s 50-day simple moving average is $190.67 and its 200 day simple moving average is $194.32. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm has a market capitalization of $143.65 billion, a PE ratio of 36.30, a PEG ratio of 2.49 and a beta of 0.78.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company earned $0.77 earnings per share. As a group, sell-side analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.